In short
A groundbreaking clinical trial is underway to evaluate the effectiveness of a personalized peptide vaccine, including Pervi-Fus, for children and young adults with metastatic fusion-driven sarcomas. This phase I/II trial aims to assess the vaccine's ability to induce T-cell responses in patients who have undergone standard treatment for Ewing sarcoma, alveolar rhabdomyosarcoma, or synovial sarcoma. The study focuses on patients in first or second complete remission or partial response, offering hope for improved outcomes in these challenging cancers.
At a glance
- Trial Name
- Personalized peptide vaccine with Pervi-Fus, Pervi-Neo, and 11902A for children and young adults with metastatic fusion-driven sarcomas
- Trial Phase
- Phase I/II
- Target Population
- Patients aged 2-40 years with metastatic Ewing sarcoma, alveolar rhabdomyosarcoma, or synovial sarcoma in first or second complete remission or partial response
- Primary Objective
- Assess individualized fusion-peptide and neopeptide vaccination-induced T-cell response
- Secondary Objectives
- Evaluate feasibility, safety/tolerability, and gather early efficacy data
- Treatment
- IPX vaccine (including Pervi-Fus) administered as an emulsion for injection
- Dosage
- Maximum daily dose: 0.3 mg; Maximum total dose: 0.9 mg
- Primary Endpoint
- Vaccination-induced T-cell response without unacceptable toxicity
- Secondary Endpoints
- T-cell responses, event-free survival, overall survival, and quality of life
What is PERVI-FUS?
PERVI-FUS is an innovative personalized peptide vaccine being studied for the treatment of certain types of metastatic sarcomas in children and young adults. It is part of a combination vaccine called IPX vaccine, which also includes two other components: PERVI-NEO and 11902A. This vaccine is designed to be tailored to each patient's specific cancer characteristics, making it a form of personalized medicine.
Target Conditions
The IPX vaccine, which includes PERVI-FUS, is being studied for patients with specific types of metastatic sarcomas, including:
- Ewing sarcoma: A rare type of cancer that occurs in bones or in the soft tissue around the bones
- Alveolar rhabdomyosarcoma: A type of soft tissue cancer that develops in muscle tissue
- Synovial sarcoma: A rare type of cancer that typically occurs near the joints of the arms or legs
These cancers are referred to as "fusion-driven" sarcomas, which means they are characterized by specific genetic changes that result in the fusion of certain genes. The study focuses on patients who have metastatic disease (cancer that has spread to other parts of the body) and are in first or second complete remission or partial response after standard treatment.
How PERVI-FUS Works
PERVI-FUS is part of a personalized vaccine approach. Here's how it works:
- The patient's tumor is analyzed using advanced genetic sequencing techniques to identify specific gene fusions and mutations.
- Based on this analysis, a personalized vaccine is created that includes peptides (small protein fragments) that match the patient's specific cancer characteristics.
- The vaccine is designed to stimulate the patient's immune system, particularly T cells, to recognize and attack the cancer cells.
The goal is to create a targeted immune response that can help prevent the cancer from returning or progressing.
Clinical Trial Details
PERVI-FUS is currently being studied in a Phase I/II clinical trial. Here are some key details about the trial:
- The main objective is to assess whether the vaccine can induce a T-cell response in patients.
- Secondary objectives include evaluating the safety and tolerability of the vaccine, as well as gathering early data on its effectiveness.
- The trial will measure the vaccine's ability to stimulate both CD8+ and CD4+ T-cell responses.
- Researchers will also track event-free survival and overall survival at 180 days after treatment.
- The study will assess patients' quality of life during treatment.
Eligibility Criteria
The trial has specific criteria for who can participate. Some key inclusion criteria are:
- Patients with confirmed metastatic fusion-driven rhabdomyosarcoma, Ewing sarcoma, or synovial sarcoma who have achieved complete remission or partial response after standard therapy.
- Availability of genetic sequencing data for the patient's tumor.
- Successful design and production of the patient's individual vaccine.
Some exclusion criteria include:
- Age below 2 or above 40 years (for stage 1 of the trial).
- Presence of other malignancies within 5 years prior to the study start.
- Certain autoimmune diseases requiring immunosuppressive treatment.
- Pregnancy or unwillingness to use contraception during the study period.
Potential Benefits and Risks
While the potential benefits of PERVI-FUS are promising, it's important to remember that this is an experimental treatment still under investigation. Possible benefits include:
- A personalized approach to cancer treatment.
- Potential to prevent cancer recurrence or progression.
- Stimulation of the body's own immune system to fight cancer.
However, as with any medical treatment, there may be risks and side effects. The clinical trial is designed to assess these risks and determine the safety of the vaccine. Patients considering participation in the trial should discuss potential risks and benefits thoroughly with their healthcare provider.